Find Reports

Select Report Type

Reimbursement Review

Displaying 476 - 500 of 1422

Please scroll or swipe to the right to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
lumacaftor/ivacaftor	Orkambi	lumacaftor/ivacaftor	SR0559 Orkambi - CDEC Final Recommendation October 4, 2018.pdf SR0559_Orkambi_CL_Report.pdf SR0559_Orkambi_PE_Report.pdf SR0559_Orkambi_PI_Submissions.pdf	Cystic Fibrosis, F508del CFTR mutation in patients 6 years and older	Do not reimburse	Complete	Feb 22, 2018	Sep 26, 2018	SR0559-000
eluxadoline	Viberzi	eluxadoline	SR0560_cdr_complete_Viberzi_Aug_29_18.pdf SR0560_Viberzi_CL_Report.pdf SR0560_Viberzi_PE_Report.pdf SR0560_Viberzi_PI_Submissions.pdf	Irritable bowel syndrome with diarrhea	Do not reimburse	Complete	Feb 23, 2018	Aug 24, 2018	SR0560-000
abobotulinumtoxinA	Dysport Therapeutic	abobotulinumtoxinA	SR0556_Dysport_Therapeutic_Aug_23_18.pdf SR0556_Dysport_Therapeutic_CL_Report.pdf SR0556_Dysport_Therapeutic_PE_Report.pdf SR0556_Dysport_PI_Submissions.pdf	lower limb spasticity	Reimburse with clinical criteria and/or conditions	Complete	Feb 7, 2018	Aug 23, 2018	SR0556-000
nitisinone	Nitisinone	nitisinone	SR0554_Nitisinone_Aug_23_18.pdf SR0554_Nitisinone_CL_Report.pdf SR0554_Nitisinone_PE_Report.pdf SR0554_Nitisinone_PI_Submissions.pdf	Hereditary tyrosinemia type 1	Reimburse with clinical criteria and/or conditions	Complete	Jan 25, 2018	Aug 23, 2018	SR0554-000
fluticasone furoate/umeclidini...	Trelegy Ellipta	fluticasone furoate umeclidinium vilanterol	SR0562_cdr_complete_Trelegy_Ellipta_Aug_27_18.pdf SR0562_TrelegyEllipta_CL_Report.pdf SR0562_TrelegyEllipta_PE_Report.pdf SR0562_TrelegyEllipta_PI_Submissions.pdf	Chronic obstructive pulmonary disease (COPD)	Reimburse with clinical criteria and/or conditions	Complete	Mar 1, 2018	Aug 23, 2018	SR0562-000
Buprenorphine hydrochloride	Probuphine	buprenorphine hydrochloride	SR0550_Probuphine_Aug_24_18.pdf SR0550_Probuphine_CL_Report.pdf SR0550_Probuphine_PE_Report.pdf	Opioid drug dependence, treatment	Reimburse with clinical criteria and/or conditions	Complete	Dec 21, 2017	Aug 22, 2018	SR0550-000
Levodopa / carbidopa (Drug Pla...	Duodopa	Levodopa / carbidopa (Drug Plan Submission)	SR0557_Duodopa_Aug_24-18.pdf SR0557_DuodopaFWG_CL_Report.pdf SR0557_DuodopaFWG_PE_Report.pdf SR0557_Duodopa_PI_Submissions.pdf si0001-duodopa-drug-implementation-advice.pdf	Parkinson's disease	Reimburse with clinical criteria and/or conditions	Complete	Feb 8, 2018	Aug 22, 2018	SR0557-000
benralizumab	Fasenra	benralizumab	SR0561_Fasenra_Aug_23_18.pdf SR0561_Fasenra_CL_Report.pdf SR0561_Fasenra_PE_Report.pdf SR0561_Fasenra_PI_Submissions.pdf	Asthma, severe eosinophilic	Reimburse with clinical criteria and/or conditions	Complete	Feb 23, 2018	Aug 21, 2018	SR0561-000
ixekizumab	Taltz	ixekizumab	SR0558_Taltz_PsA_Aug_23_18.pdf SR0558_TaltzPsA_CL_Report.pdf SR0558_TaltzPsA_PE_Report.pdf SR0558_TaltzPsA_PI_Submissions.pdf	Arthritis, psoriatic	Reimburse with clinical criteria and/or conditions	Complete	Feb 20, 2018	Aug 21, 2018	SR0558-000
Alecensaro for Non-Small Cell ...	Alecensaro	Alectinib	pcodr_provfund_alectinib_alecensaro_nsclc_1ln.pdf pcodr_alectinib_alecensaro_nsclc_1stln_fn_rec.pdf pcodr_alectinib_alecensaro_nsclc_1stln_fn_cgr.pdf pcodr_alectinib_alecensaro_nsclc_1stln_fn_egr.pdf pcodr_alectinib_alecensaro_nsclc_1stln_in_rec.pdf pcodr_alectinib_alecensaro_nsclc_1stln_pagfdk.pdf pcodr_alectinib_alecensaro_nsclc_1stln_fdk_hlr.pdf pcodr_alectinib_alecensaro_nsclc_1stln_clnfdk.pdf pcodr_alectinib_alecensaro_nsclc_1stln_coi_pt.pdf pcodr_alectinib_alecensaro_nsclc_1stln_coi_cln.pdf	Locally advanced or metastatic ALK+ NSCLC (first line)	Reimburse with clinical criteria and/or conditions	Complete	Jan 15, 2018	Jul 25, 2018	PC0125-000
Darunavir/cobicistat/emtricita...	Symtuza	Darunavir/cobicistat/emtricitabine/tenofovir alafenamide	SR0552_cdr_complete_Symtuza_July_27_18.pdf SR0552_Symtuza_Combined_Report.pdf SR0552_Symtuza_PI_Submissions.pdf	HIV-1 infection	Reimburse with clinical criteria and/or conditions	Complete	Dec 22, 2017	Jul 25, 2018	SR0552-000
Lonsurf for Metastatic Colorec...	Lonsurf	Trifluridine and Tipiracil	pcodr_provfund_trifluridine_tipiracil_lonsurf_mcrc.pdf pcodr_trifluridine_tipiracil_lonsurf_mcrc_fn_rec.pdf pcodr_trifluridine_tipiracil_lonsurf_mcrc_fn_cgr.pdf pcodr_trifluridine_tipiracil_lonsurf_mcrc_fn_egr.pdf pcodr_trifluridine-tipiracil_Lonsurf_mCRC_in_rec.pdf pcodr_trifluridine_tipiracil_lonsurf_mcrc_pagfdk.pdf pcodr_trifluridine_tipiracil_lonsurf_mcrc_fdk_taiho.pdf pcodr_trifluridine_tipiracil_lonsurf_mcrc_ptfdk.pdf pcodr_trifluridine_tipiracil_lonsurf_mcrc_clnfdk.pdf pcodr_trifluridine_tipiracil_lonsurf_mcrc_coi_pt.pdf pcodr_trifluridine_tipiracil_lonsurf_mcrc_coi_cln.pdf	Metastatic Colorectal Cancer	Do not reimburse	Complete	Nov 6, 2017	Jul 6, 2018	PC0122-000
Besponsa for Acute Lymphoblast...	Besponsa	Inotuzumab Ozogamicin	pcodr_provfund_inotuzumab-ozogamicin_besponsa_all.pdf pcodr_inotuzumab_ozogamicin_besponsa_all_fn_rec.pdf pcodr_inotuzumab_ozogamicin_besponsa_all_fn_cgr.pdf pcodr_inotuzumab_ozogamicin_besponsa_all_fn_egr.pdf pcodr_inotuzumab_besponsa_ALL_in_rec.pdf pcodr_inotuzumab_ozogamicin_besponsa_all_pagfdk.pdf pcodr_inotuzumab_ozogamicin_besponsa_all_fdk_pfizer.pdf pcodr_inotuzumab_ozogamicin_besponsa_all_clnfdk.pdf pcodr_inotuzumab_ozogamicin_besponsa_all_coi_pt.pdf pcodr_inotuzumab_ozogamicin_besponsa_all_coi_cln.pdf	Acute Lymphoblastic Leukemia (ALL)	Reimburse with clinical criteria and/or conditions	Complete	Nov 13, 2017	Jul 6, 2018	PC0121-000
dupilumab	Dupixent	dupilumab	SR0533_cdr_complete_Dupixent_July_9_2018.pdf SR0533_Dupixent_CL_Report.pdf SR0533_Dupixent_PE_Report.pdf SR0533_Duxipent_Patient_Submsissions.pdf	atopic dermatitis	Do not reimburse	Complete	Oct 27, 2017	Jun 27, 2018	SR0533-000
netupitant / palonosetron	Akynzeo	netupitant / palonosetron	SR0548_cdr_complete_Akynzeo_June_22_18.pdf SR0548_Akynzeo_CL_Report.pdf SR0548_Akynzeo_PE_Report.pdf	Nausea and vomiting (chemotherapy induced) prevention	Reimburse with clinical criteria and/or conditions	Complete	Dec 8, 2017	Jun 20, 2018	SR0548-000
Tecentriq for Non-Small Cell L...	Tecentriq	Atezolizumab	pcodr_profund_10115_atezolizumab_tecentriq_nsclc.pdf pcodr_atezolizumab_tecentriq_nsclc_fn_rec.pdf pcodr_atezolizumab_tecentriq_nsclc_fn_cgr.pdf pcodr_atezolizumab_tecentriq_nsclc_fn_egr.pdf pcodr_atezolizumab_tecentriq_nsclc_in_rec.pdf pcodr_atezolizumab_tecentriq_nsclc_pagfdk.pdf pcodr_atezolizumab_tecentriq_nsclc_fdk_hlroche.pdf pcodr_atezolizumab_tecentriq_nsclc_clnfdk.pdf pcodr_atezolizumab_tecentriq_nsclc_coi_pt.pdf pcodr_atezolizumab_tecentriq_nsclc_coi_cln.pdf	Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)	Reimburse with clinical criteria and/or conditions	Complete	Dec 15, 2017	Jun 20, 2018	PC0115-000
Dolutegravir / rilpivirine	Juluca	Dolutegravir rilpivirine	SR0551_cdr_complete_Juluca_June_22_18.pdf SR0551_Juluca_CL_Report.pdf SR0551_Juluca_PE_Report.pdf SR0551_Juluca_PI_Submissions.pdf	HIV infection	Reimburse with clinical criteria and/or conditions	Complete	Dec 21, 2017	Jun 20, 2018	SR0551-000
letermovir	Prevymis	letermovir	SR0545_cdr_complete_Prevymis_June_22_2018.pdf SR0545_Prevymis_CL_Report.pdf SR0545_Prevymis_PE_Report.pdf SR0545_Prevymis_PI_Submissions.pdf	Cytomegalovirus infection, prophylaxis	Reimburse with clinical criteria and/or conditions	Complete	Dec 7, 2017	Jun 20, 2018	SR0545-000
brodalumab	Siliq	brodalumab	TS0001-PsO-Updated-Streamlined-Rec.pdf SR0547_cdr_complete_Siliq_June_22_18.pdf SR0547_Siliq_CL_Report.pdf SR0547_Siliq_PE_Report.pdf SR0547_Brodalumab_PI_Submissions.pdf	Psoriasis, moderate to severe plaque	Reimburse with clinical criteria and/or conditions	Complete	Dec 14, 2017	Jun 20, 2018	SR0547-000
Opdivo for classical Hodgkin L...	Opdivo	Nivolumab	pcodr_profund_nivolumab_opdivo_chl_fail_asct.pdf pcodr_nivolumab_opdivo_cHL_fn_rec.pdf pcodr_nivolumab_opdivo_cHL_fn_egr.pdf pcodr_nivolumab_opdivo_cHL_fn_cgr.pdf pcodr_nivolumab_opdivo_chl_in_rec.pdf pcodr_nivolumab_opdivo_cHL_pagfdk.pdf pcodr_nivolumab_opdivo_cHL_ptfdk.pdf pcodr_nivolumab_opdivo_cHL_clnfdk.pdf pcodr_nivolumab_opdivo_cHL_fdk_bms.pdf pcodr_nivolumab_opdivo_cHL_coi_pt.pdf pcodr_nivolumab_opdivo_cHL_coi_cln.pdf	classical Hodgkin Lymphoma (cHL) after failure of ASCT	Reimburse with clinical criteria and/or conditions	Complete	Sep 29, 2017	May 3, 2018	PC0120-000
ocrelizumab	Ocrevus	ocrelizumab	SR0542_cdr_complete_Ocrevus_PPMS_Apr_30_18_e.pdf SR0542_Ocrevus_PPMS_CL_Report.pdf SR0542_Ocrevus_PPMS_PE_Report.pdf SR0542_Ocrevus_PPMS_PI_Submissions.pdf	Primary progressive multiple sclerosis	Reimburse with clinical criteria and/or conditions	Complete	Oct 26, 2017	Apr 26, 2018	SR0542-000
nitisinone	MDK-Nitisinone	nitisinone	SR0538_cdr_complete_MDK_Nitisinone_Apr_27_18_e.pdf SR0538_MDK_Nitisinone_CL_Report.pdf SR0538_MDK_Nitisinone_PE_Report.pdf SR0538_MDK_Nitisinone_PI_Submissions.pdf	Hereditary tyrosinemia type 1	Reimburse with clinical criteria and/or conditions	Complete	Sep 29, 2017	Apr 25, 2018	SR0538-000
latanoprost	Monoprost	latanoprost	SR0541_cdr_complete_Monoprost_apr-26-18_e.pdf SR0541_Monoprost_CL_Report.pdf SR0541_Monoprost_PE_Report.pdf	glaucoma and ocular hypertension	Reimburse with clinical criteria and/or conditions	Complete	Oct 25, 2017	Apr 24, 2018	SR0541-000
Lartruvo for Advanced Soft Tis...	Lartruvo	Olaratumab	pcodr_profund_olaratumab_lartruvo_sts.pdf pcodr_olaratumab_lartruvo_sts_fn_rec.pdf pcodr_olaratumab_lartruvo_sts_fn_cgr.pdf pcodr_olaratumab_lartruvo_sts_fn_egr.pdf pcodr_olaratumab_lartruvo_sts_in_rec.pdf pcodr_olaratumab_lartruvo_sts_pagfdk.pdf pcodr_olaratumab_lartruvo_sts_fdk_elc.pdf pcodr_olaratumab_lartruvo_sts_clnfdk.pdf pcodr_olaratumab_lartruvo_sts_coi_pt.pdf pcodr_olaratumab_lartruvo_sts_coi_cln.pdf	Advanced Soft Tissue Sarcoma	Reimburse with clinical criteria and/or conditions	Complete	Oct 26, 2017	Apr 18, 2018	PC0111-000
Stivarga for Unresectable Hepa...	Stivarga	Regorafenib	pcodr_provfund_10119_regorafenib_stivarga_unresectable_hcc.pdf pcodr_regorafenib_stivarga_hcc_fn_rec.pdf pcodr_regorafenib_stivarga_hcc_fn_cgr.pdf pcodr_regorafenib_stivarga_hcc_fn_egr.pdf pcodr_regorafenib_stivarga_hcc_in_rec.pdf pcodr_regorafenib_stivarga_hcc_pagfdk.pdf pcodr_regorafenib_stivarga_hcc_fdk_bayer.pdf pcodr_regorafenib_stivarga_hcc_ptfdk.pdf pcodr_regorafenib_stivarga_hcc_clnfdk.pdf pcodr_regorafenib_stivarga_hcc_coi_pt.pdf pcodr_regorafenib_stivarga_hcc_coi_cln.pdf	Unresectable Hepatocellular Carcinoma (HCC)	Reimburse with clinical criteria and/or conditions	Complete	Oct 12, 2017	Apr 18, 2018	PC0119-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 476 - 500 of 600

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Capsaicin for Acute or Chronic Non-Cancer Pain: A Review of Guidelines	Capsaicin for Acute or Chronic Non-Cancer Pain: A Review of Guidelines	Jun 29, 2020	Summary with Critical Appraisal	Completed	RC1287-000
Transcatheter Aortic Valve Implantation for Degenerated Mitral or Tricuspid Bioprostheses: A Review of Clinical Effectiveness and Cost-Effectiveness		Jun 29, 2020	Summary with Critical Appraisal		RC1283-000
Preoperative Interventions for the Prevention of Surgical Site Infections: A Review of Guidelines	RC1279 Nasal Decolonization Guideline Upgrade Final.pdf	Jun 29, 2020	Summary with Critical Appraisal		RC1279-000
Gender Affirming Therapy for Gender Dysphoria: A Rapid Qualitative Review	RC1266 PP&E GAT for GD Final.pdf	Jun 29, 2020	Summary with Critical Appraisal	Completed	RC1266-000
Pioglitazone for Type 2 Diabetes Mellitus and Pre-Diabetes: A Review of Safety	RC1285 Pioglitazone AE Final.pdf	Jun 22, 2020	Summary with Critical Appraisal	Completed	RC1285-000
Experiences and Perspectives of Treatments for Heart Valve Disease: A Rapid Qualitative Review	RC1289 Treatment of Heart Valve Disease Qual__Final.pdf	Jun 22, 2020	Summary with Critical Appraisal		RC1289-000
Adalimumab for Adult Patients with Plaque Psoriasis: A Review of Clinical Effectiveness	RC1274 Adalimumab for Plaque Psoriasis Final.pdf	Jun 22, 2020	Summary with Critical Appraisal	Completed	RC1274-000
MRI-Compatible Ventilators and Physiological Equipment for Adults Undergoing MRI exams: A Review of Clinical Effectiveness and Guidelines	MRI-Compatible Ventilators and Physiological Equipment for Adults Undergoing MR…	Jun 20, 2020	Rapid Review	Completed	RC0996-000
Off-Loading Devices for People with Diabetic Neuropathic Foot Ulcers: A Rapid Qualitative Review	RC1286 Diabetes Offloading Devices Final.pdf	Jun 17, 2020	Summary with Critical Appraisal	Completed	RC1286-000
Transcatheter Mitral Valve Repair Device for the Treatment of Tricuspid or Tricuspid and Mitral Regurgitation: A Review of Clinical Effectiveness and Cost-Effectiveness	RC1282 MitraClip Tricuspid Regurgitation Final.pdf	Jun 12, 2020	Summary with Critical Appraisal	Completed	RC1282-000
Adalimumab for Adult Patients with Rheumatological Disorders: A Review of Clinical Effectiveness	RC1273 Adalimumab for Rheumatology Final erratum.pdf	Jun 2, 2020	Summary with Critical Appraisal	Completed	RC1273-000
Injectable Opioid Agonist Treatment for Patients with Opioid Dependence: A Review of Clinical and Cost-Effectiveness	RC1277-iOAT Final.pdf	Jun 2, 2020	Summary with Critical Appraisal	Completed	RC1277-000
Ketamine for Chronic Non-Cancer Pain: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1281 - Ketamine for CNCP Final.pdf	Jun 2, 2020	Summary with Critical Appraisal	Completed	RC1281-000
Nasal Decolonization for the Prevention of Surgical Site Infections: A Review of Clinical Effectiveness and Cost-Effectiveness	RC1278 Nasal Decolonization Clinical and Cost Upgrade Final.pdf	May 28, 2020	Summary with Critical Appraisal		RC1278-000
Adalimumab for Adult Patients with Crohn’s Disease: A Review of Clinical Effectiveness	RC1272 Adalimumab for Crohns Final.pdf	May 14, 2020	Summary with Critical Appraisal		RC1272-000
Tools		May 14, 2020
External Supports for the Treatment of Ankle Sprain: A Review of Clinical Effectiveness	RC1263 External Supports Ankle Sprain Final.pdf	May 7, 2020	Summary with Critical Appraisal	Completed	RC1263-000
Comparative Assessment of Coverage Criteria for Biologic Disease-Modifying Antirheumatic Drugs Across Canadian Public Drug Plans: An Environmental Scan		May 5, 2020	Environmental Scan	Completed	ES0351-000
Pharmacological Interventions for Chronic Pain in Pediatric Patients: A Review of Guidelines	RC1275 Ped Chronic Pain Guidelines Final.pdf	May 5, 2020	Summary with Critical Appraisal	Completed	RC1275-000
Vein Illumination Devices in Long-Term and Acute Care Settings: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines	RC1268 Vein Illumination Devices Final.pdf	May 4, 2020	Summary with Critical Appraisal		RC1268-000
Islet Cell Transplantation for Patients with Unstable or Uncontrollable Diabetes Mellitus: Clinical Effectiveness. Cost-Effectiveness and Guidelines	RC1270- ICT Final.pdf	May 4, 2020	Summary with Critical Appraisal	Completed	RC1270-000
Transanal Total Mesorectal Excision for Adult Patients with Rectal Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness	RC1271 TaTME Final.pdf	May 4, 2020	Summary with Critical Appraisal	Completed	RC1271-000
Primary Care Initiated Gender-Affirming Therapy for Gender Dysphoria: A Review of Evidence Based Guidelines	RC1267 Primary Care Initiated GAT for GD Final.pdf	May 1, 2020	Summary with Critical Appraisal	Completed	RC1267-000
Pleuroscopy for the Diagnosis of Cancer in Patients with Pleural Effusion: A Review of the Diagnostic Accuracy, Safety, Cost-Effectiveness and Guidelines	RC1260 Pleuroscopy Final.pdf	Apr 27, 2020	Summary with Critical Appraisal	Completed	RC1260-000
Psychotherapy for the Treatment of Acute Musculoskeletal Pain: A Review of Clinical Effectiveness and Guidelines	RC1262 Psychotherapy Acute Pain Final.pdf	Apr 27, 2020	Summary with Critical Appraisal	Completed	RC1262-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 476 - 500 of 2132

Please scroll or swipe to the right to view the full content.

Title	Description	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Chronic Lymphocytic Leukemia		Final Report	Mar 21, 2024	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0038 -000
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Type 2 Diabetes Mellitus, Heart Failure, and Chronic Kidney Disease	This Environmental Scan assesses the current reimbursement of the SGLT2 drug class relevant to public drug programs, including the regulatory, exclusivity, reimbursement review, and reimbursement status of these drugs for type 2 diabetes mellitus, heart failure, and chronic kidney disease.	Final Report	Mar 19, 2024	Horizon Scan	Environmental Scan	Completed	ES0370-000
NovoTTF-200A		Recommendation and Reasons CADTH Summary Report Stakeholders Input Supplemental Materials report	Mar 19, 2024	Health Technology Review	Optimal Use	Completed	OP0554-000
Utilization Analysis of Tofacitinib and Other Drugs Among Individuals With Ulcerative Colitis: Feasibility Analysis		Summary Report Final Report Protocol: Utilization Analysis of Tofacitinib and Other Drugs Among Individuals…	Mar 14, 2024	Health Technology Review	Observational Study	Complete	OS0003-000
Reprocessed Single-Use Semicritical and Critical Medical Devices	We sought to identify and summarize literature evaluating the clinical safety of reprocessed single-used medical devices (SUMDs), defined as infections, mortality, or other adverse events, compared with nonreprocessed (new) SUMDs.	Reprocessed Single-Use Semicritical and Critical Medical Devices	Mar 14, 2024	Health Technology Review	Rapid Review	Completed	RC1511-000
upadacitinib		Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Mar 14, 2024	Reimbursement Review		Complete	SR0775-000
Aerosol Therapy With Inhalers During Mechanical Ventilation		Aerosol Therapy With Inhalers During Mechanical Ventilation	Mar 12, 2024	Health Technology Review	Rapid Review	Completed	RC1529-000
Pan- Canadian Rare Disease Registries		Assessing Canadian Rare Disease Patient Registries for Real-World Evidence Usin…	Mar 11, 2024	Health Technology Review	Environmental Scan	Completed	ES0369-000
andexanet alfa		Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder feedback on Draft Recommendation	Mar 8, 2024	Reimbursement Review		Complete	ST0772-000
Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes Mellitus		Streamlined Drug Class Review - Final Recommendation and Reasons Updated CADTH Reimbursement Recommendations CADTH Review - Final Summary Report Supplemental Materials	Mar 7, 2024	Reimbursement Review	Streamlined Drug Class Review	Complete	TS0002-000
Ketamine for Adults With Substance Use Disorders	To inform decisions about using ketamine for treating SUDs, we sought to identify and summarize the literature comparing the clinical and cost-effectiveness of ketamine with placebo or no treatment, with alternative interventions, or among ketamine administered via different routes for SUDs.	Ketamine for Adults With Substance Use Disorders	Mar 7, 2024	Health Technology Review	Rapid Review	Completed	RC1523-000
Intra-Articular Hyaluronic Acid for Osteoarthritis of the Hip, Shoulder, and Ankle		Intra-Articular Hyaluronic Acid for Osteoarthritis of the Hip, Shoulder, and Ankle	Mar 6, 2024	Health Technology Review	Rapid Review	Completed	RC1528-000
Opioid-Sparing Effects of IV Acetaminophen for Patients Undergoing Surgery		Opioid-Sparing Effects of IV Acetaminophen for Patients Undergoing Surgery	Mar 6, 2024	Health Technology Review	Rapid Review	Completed	RC1530-000
2024 Watch List: Care for Children and Youth With Medical Complexity	The 2024 Watch List aims to identify and describe technologies and issues related to the care of children and youth with medical complexity that are likely to affect health care delivery and planning in Canada in the next 5 years.	2024-watch-list-report.pdf	Mar 5, 2024	Horizon Scan	Roundup	Completed	ER0014-000
Photon-Counting CT: High Resolution, Less Radiation	CT scanners play an essential role as medical imaging devices for screening, diagnosis, and monitoring of various health conditions. Photon-counting CT (PCCT) is an emerging medical technology that can improve image quality with less radiation exposure.	La tomodensitométrie à comptage photonique améliore la résolution et réduit l’irradiation	Mar 4, 2024	Horizon Scan	Emerging Health Technologies	Completed	EH0124-000
CADTH Pharmaceutical Reviews Update — Issue 44			Feb 29, 2024	Reimbursement Review	Pharmaceutical Review Update
polatuzumab vedotin		Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Feb 28, 2024	Reimbursement Review		Complete	PC0313-000
Cost-Effectiveness of Respiratory Syncytial Virus Vaccines for Adults		Cost-Effectiveness of Respiratory Syncytial Virus Vaccines for Adults	Feb 26, 2024	Health Technology Review	Technology Review	Completed	HE0047 -000
Timing of Antibiotic Therapy for Neisseria Gonorrhoeae Infection		Timing of Antibiotic Therapy for Neisseria Gonorrhoeae Infection	Feb 24, 2024	Health Technology Review	Rapid Review	Completed	RC1527-000
Clinical and Instrumental Swallowing Assessments for Dysphagia		Clinical and Instrumental Swallowing Assessments for Dysphagia	Feb 23, 2024	Health Technology Review	Rapid Review	Completed	RC1526-000
Renal cell carcinoma		Final Report	Feb 21, 2024	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0037-000
cabozantinib		Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Feb 15, 2024	Reimbursement Review		Complete	PC0312-000
elexacaftor/tezacaftor/ivacaftor and ivacaftor		Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Feb 9, 2024	Reimbursement Review		Complete	SR0776-000
mirikizumab		Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Feb 9, 2024	Reimbursement Review		Complete	SR0773-000
ibrutinib		Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Feb 9, 2024	Reimbursement Review		Complete	PC0317-000